{"id":770887,"date":"2025-10-27T18:19:01","date_gmt":"2025-10-27T18:19:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=770887"},"modified":"2025-10-27T18:19:01","modified_gmt":"2025-10-27T18:19:01","slug":"infectious-disease-diagnostics-market-to-reach-usd-4220-billion-by-2030-rapid-molecular-testing-aidriven-platforms-lead-growth","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/infectious-disease-diagnostics-market-to-reach-usd-4220-billion-by-2030-rapid-molecular-testing-aidriven-platforms-lead-growth_770887.html","title":{"rendered":"Infectious Disease Diagnostics Market to Reach USD 42.20 Billion by 2030 | Rapid Molecular Testing &#038; AI-driven Platforms Lead Growth"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/10\/1761553411.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Infectious Disease Diagnostics Market to Reach USD 42.20 Billion by 2030 | Rapid Molecular Testing &amp; AI-driven Platforms Lead Growth\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/10\/1761553411.jpg\" alt=\"Infectious Disease Diagnostics Market to Reach USD 42.20 Billion by 2030 | Rapid Molecular Testing &amp; AI-driven Platforms Lead Growth\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Global infectious disease diagnostics market valued at $24.96B in 2024, $26.58B in 2025, and set to hit $40.20B by 2030, growing at 9.7% CAGR.<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Infectious Disease Diagnostics Industry News Update: Infectious disease diagnostics market projected to reach $42.20 billion by 2030.<\/div>\n<p style=\"text-align: justify;\">The <strong>global <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/infectious-disease-diagnostics-market-116764589.html\"><strong>infectious disease diagnostics market<\/strong><\/a> is projected to reach <strong>USD 42.20 billion by 2030<\/strong>, up from <strong>USD 26.58 billion in 2025<\/strong>, growing at a <strong>CAGR of 9.7%<\/strong> during the forecast period, according to the latest <strong>MarketsandMarkets&trade;<\/strong> report. The market&rsquo;s expansion is fueled by the <strong>rising global incidence of infectious diseases<\/strong>, growing <strong>demand for early and accurate testing<\/strong>, and <strong>technological innovations<\/strong> in <strong>molecular diagnostics<\/strong> and <strong>point-of-care (PoC)<\/strong> testing.<\/p>\n<p style=\"text-align: justify;\"><strong>Market Overview: The Rising Demand for Accurate and Rapid Disease Testing<\/strong><\/p>\n<p style=\"text-align: justify;\">The growing global burden of infectious diseases&mdash;including <strong>HIV, tuberculosis, influenza, hepatitis, and healthcare-associated infections (HAIs)<\/strong>&mdash;has accelerated the adoption of <strong>advanced diagnostic technologies<\/strong>. Recurring outbreaks, such as those caused by <strong>novel respiratory viruses<\/strong>, and the <strong>emergence of antimicrobial resistance (AMR)<\/strong>, have underscored the importance of <strong>rapid and precise diagnostic tools<\/strong>.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Growth Drivers:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Increasing global prevalence of <strong>infectious and emerging diseases<\/strong><\/li>\n<li>Growing focus on <strong>early detection and personalized treatment<\/strong><\/li>\n<li>Continuous <strong>technological advancements<\/strong> in molecular and PoC diagnostics<\/li>\n<li>Expansion of <strong>healthcare infrastructure<\/strong> in developing economies<\/li>\n<li>Rising <strong>government investments<\/strong> in public health surveillance<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Together, these factors are driving strong growth across clinical laboratories, hospitals, and research institutions, as healthcare systems prioritize <strong>diagnostic accuracy and turnaround speed<\/strong>.<\/p>\n<p style=\"text-align: justify;\"><strong>Download PDF: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=116764589&amp;utm_source=abnewswire.com&amp;utm_medium=referral&amp;utm_campaign=paidpr\" target=\"_blank\"><strong>https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=116764589<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>By Product &amp; Service: Reagents, Kits, and Consumables Dominate the Market<\/strong><\/p>\n<p style=\"text-align: justify;\">The market is segmented into <strong>reagents, kits, and consumables<\/strong>; <strong>instruments<\/strong>; and <strong>software &amp; services<\/strong>. In 2024, <strong>reagents, kits, and consumables<\/strong> accounted for the <strong>largest market share<\/strong> and are expected to maintain dominance through 2030.<\/p>\n<p style=\"text-align: justify;\"><strong>Why This Segment Leads:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>High <strong>testing frequency<\/strong> and <strong>recurring demand<\/strong> among end users<\/li>\n<li>Critical role in ensuring <strong>test reliability and sensitivity<\/strong><\/li>\n<li>Continuous product innovation in <strong>multiplex assays and rapid test kits<\/strong><\/li>\n<li>Increasing use of <strong>AI-enhanced molecular reagents<\/strong> for faster data interpretation<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">This recurring revenue stream is vital for diagnostic companies, as consumable purchases represent a stable, long-term growth opportunity.<\/p>\n<p style=\"text-align: justify;\"><strong>By Sample Type: Blood, Serum, and Plasma Lead Testing Applications<\/strong><\/p>\n<p style=\"text-align: justify;\">Based on sample type, the market is segmented into <strong>blood, serum, and plasma<\/strong>; <strong>urine<\/strong>; and <strong>other samples<\/strong>. In 2024, <strong>blood, serum, and plasma samples<\/strong> dominated due to their <strong>rich diagnostic value<\/strong> and ability to reveal multiple biomarkers and pathogens.<\/p>\n<p style=\"text-align: justify;\">These samples provide comprehensive biological data for <strong>PCR<\/strong>, <strong>ELISA<\/strong>, <strong>NGS<\/strong>, and <strong>immunodiagnostic assays<\/strong>, enabling healthcare professionals to:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Detect infections in <strong>early stages<\/strong><\/li>\n<li>Monitor <strong>disease progression<\/strong><\/li>\n<li>Support <strong>personalized therapy planning<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The continued evolution of <strong>liquid biopsy<\/strong> and <strong>microfluidic diagnostic platforms<\/strong> is expected to further enhance blood-based testing capabilities.<\/p>\n<p style=\"text-align: justify;\"><strong>By Technology: Molecular Diagnostics Driving Accuracy and Speed<\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong>infectious disease diagnostics market<\/strong> is transforming through the adoption of <strong>advanced molecular technologies<\/strong>, including:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Polymerase Chain Reaction (PCR)<\/strong><\/li>\n<li><strong>Next-Generation Sequencing (NGS)<\/strong><\/li>\n<li><strong>Isothermal Amplification<\/strong><\/li>\n<li><strong>Immunodiagnostics (ELISA, rapid antigen tests)<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Emerging Trends:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Miniaturized <strong>point-of-care PCR platforms<\/strong><\/li>\n<li>Integration of <strong>AI-based image and data analysis<\/strong><\/li>\n<li>Multi-pathogen <strong>syndromic testing panels<\/strong><\/li>\n<li>Cloud-enabled diagnostic connectivity for <strong>remote healthcare settings<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The fusion of molecular diagnostics with <strong>digital health technologies<\/strong> enables <strong>faster, decentralized testing<\/strong>, improving outbreak management and patient outcomes.<\/p>\n<p style=\"text-align: justify;\"><strong>By Region: North America Leads Global Market Share<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>North America<\/strong> accounted for the <strong>largest share<\/strong> of the <strong>infectious disease diagnostics market<\/strong> in 2024, supported by:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Advanced <strong>healthcare infrastructure<\/strong><\/li>\n<li>High diagnostic <strong>testing rates<\/strong><\/li>\n<li>Early adoption of <strong>AI and automation<\/strong> in laboratories<\/li>\n<li>Continuous R&amp;D investment by leading diagnostic manufacturers<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The <strong>United States<\/strong> remains a global innovation hub, driven by <strong>FDA approvals<\/strong>, strong <strong>public-private partnerships<\/strong>, and <strong>government initiatives<\/strong> to strengthen disease surveillance systems.<\/p>\n<p style=\"text-align: justify;\">Meanwhile, the <strong>Asia Pacific region<\/strong> is expected to witness the <strong>fastest growth<\/strong>, supported by:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Rapid healthcare modernization in <strong>China, India, and South Korea<\/strong><\/li>\n<li>Expanding diagnostic access in <strong>rural and underserved areas<\/strong><\/li>\n<li>Growing focus on <strong>infectious disease prevention and control programs<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Innovation Spotlight: AI and Point-of-Care Diagnostics Revolutionizing Testing<\/strong><\/p>\n<p style=\"text-align: justify;\">Emerging technologies are transforming how healthcare providers detect and manage infectious diseases:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>AI-powered diagnostic platforms<\/strong> enhance test interpretation, reducing false negatives and improving clinical decision-making.<\/li>\n<li><strong>Portable point-of-care devices<\/strong> enable testing in decentralized environments, from clinics to home care.<\/li>\n<li><strong>Cloud-based connectivity<\/strong> supports real-time data sharing and outbreak monitoring.<\/li>\n<li><strong>NGS-based pathogen identification<\/strong> facilitates comprehensive surveillance of evolving strains and resistance patterns.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">These innovations are central to achieving <strong>global health resilience<\/strong> and <strong>precision-based public health strategies<\/strong>.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Market Players<\/strong><\/p>\n<p style=\"text-align: justify;\">Leading companies shaping the <strong>infectious disease diagnostics landscape<\/strong> include: <strong>F. Hoffmann-La Roche Ltd. (Switzerland)<\/strong>, <strong>Abbott (US)<\/strong>, <strong>Danaher Corporation (US)<\/strong>, <strong>bioM&eacute;rieux (France)<\/strong>, <strong>Thermo Fisher Scientific Inc. (US)<\/strong>, <strong>Siemens Healthineers AG (Germany)<\/strong>, <strong>Becton, Dickinson and Company (US)<\/strong>, <strong>Hologic, Inc. (US)<\/strong>, <strong>QIAGEN N.V. (Netherlands)<\/strong>, and <strong>Bio-Rad Laboratories, Inc. (US)<\/strong>.<\/p>\n<p style=\"text-align: justify;\">These companies are investing in <strong>AI-enabled diagnostic automation<\/strong>, <strong>portable molecular testing<\/strong>, and <strong>syndromic panels<\/strong>, driving innovation across clinical and research applications.<\/p>\n<p style=\"text-align: justify;\"><strong>Conclusion: Diagnostics at the Core of Global Health Preparedness<\/strong><\/p>\n<p style=\"text-align: justify;\">As infectious threats evolve, <strong>accurate, rapid, and decentralized testing<\/strong> has become essential to global health strategies. The <strong>infectious disease diagnostics market<\/strong> is poised for sustained growth, powered by <strong>molecular innovations<\/strong>, <strong>AI-driven platforms<\/strong>, and <strong>expanding diagnostic infrastructure<\/strong> in both developed and emerging economies.<\/p>\n<p style=\"text-align: justify;\">With increasing global health challenges, <strong>diagnostics remains the cornerstone<\/strong> of effective disease prevention, timely treatment, and population-level surveillance.<\/p>\n<p style=\"text-align: justify;\"><strong>Request Sample Pages: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=116764589&amp;utm_source=abnewswire.com&amp;utm_medium=referral&amp;utm_campaign=paidpr\" target=\"_blank\"><strong>https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=116764589<\/strong><\/a><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/marketsandmarkets.com_145966.html\" rel=\"nofollow\">MarketsandMarkets\u2122 Research Private Ltd.<\/a><br \/><strong>Contact Person:<\/strong> Mr. Rohan Salgarkar<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=infectious-disease-diagnostics-market-to-reach-usd-4220-billion-by-2030-rapid-molecular-testing-aidriven-platforms-lead-growth\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 18886006441<br \/><strong>Address:<\/strong>1615 South Congress Ave.  Suite 103, Delray Beach, FL 33445<br \/><strong>City:<\/strong> Florida<br \/><strong>State:<\/strong> Florida<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/infectious-disease-diagnostics-market-116764589.html\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.marketsandmarkets.com\/Market-Reports\/infectious-disease-diagnostics-market-116764589.html<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=infectious-disease-diagnostics-market-to-reach-usd-4220-billion-by-2030-rapid-molecular-testing-aidriven-platforms-lead-growth\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Global infectious disease diagnostics market valued at $24.96B in 2024, $26.58B in 2025, and set to hit $40.20B by 2030, growing at 9.7% CAGR. Infectious Disease Diagnostics Industry News Update: Infectious disease diagnostics market projected to reach $42.20 billion by &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/infectious-disease-diagnostics-market-to-reach-usd-4220-billion-by-2030-rapid-molecular-testing-aidriven-platforms-lead-growth_770887.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-770887","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/770887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=770887"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/770887\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=770887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=770887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=770887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}